Skip to main content
. 2009 Jan 21;2009(1):CD006153. doi: 10.1002/14651858.CD006153.pub2

Parry 2010.

Methods Randomized, dose‐escalation
Participants United States
N = 18 (15 mg/day: 7, 30 mg/day: 4, 50 mg/day: 7)
Mean age 48.9 years (15 mg/d), 58.3 years (30 mg/d), 56.6 years (50 mg/d)
Gender distribution, male (%): 57.1% (15 mg/d), 50% (30 mg/d), 57.1% (50 mg/d)
Family history of ALS not reported in published manuscript
Interventions Ursodeocycholic acid
15 mg/day, 30 mg/day and 50 mg/day
Outcomes Primary: safety and tolerability
Notes Funded by Axcan Pharma Inc.